Bryan Johnson Eyes Sale of Anti-Aging Company, Cites "Pain-In-The-Ass" Business

 Bryan Johnson Eyes Sale of Anti-Aging Company, Cites "Pain-In-The-Ass" Business

Bryan Johnson, the US-based biotech entrepreneur famous for his pursuit of defying death and promoting the "Don't Die" ideology, has indicated his intent to sell his anti-aging startup, Blueprint. Johnson, who reportedly spends $2 million annually on a rigorous regimen of medical diagnostics, treatments, diet, sleep, and exercise to slow or even reverse aging, told Wired that juggling his business ventures and philosophical interests has become too challenging.

"Honestly, I am so close to either shutting it down or selling it," Johnson revealed, emphasizing that he doesn't need the money and finds the company to be a significant burden. He stated, "The problem is now people see the business and give me less credibility on the philosophy side. I will not make that trade-off. It is not worth it to me. So yeah, I don't want it."

Johnson's company, Blueprint, sells wellness products purported to aid customers in slowing their aging process. Recent reports, including one from The New York Times, have raised questions about the integrity of these products and the financial health of the startup. When asked if the Times' report was a factor in his decision, Johnson vehemently denied it.

"It has nothing to do with The New York Times. I am not hiding from The New York Times article. I'm happy to take, head-on, every single allegation they made. I will say [their reporting on] the business, that was f---ing made up," he asserted                             

                                                                       

The New York Times report claimed Blueprint was struggling financially, missing its break-even point by at least $1 million a month despite increased revenue, and stated that Johnson, as the sole investor with $25 million invested, had warned executives about the company running out of money.

However, Johnson refutes these financial troubles, despite his consideration of shutting down or selling the company. "We are break-even, and I've said that publicly many times. We've had profitable months, we've had loss months," he clarified.